DURECT Corporation (NASDAQ:DRRX) – Equities research analysts at Zacks Investment Research increased their FY2017 EPS estimates for shares of DURECT Corporation in a research note issued on Thursday. Zacks Investment Research analyst G. Zeng now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.13) for the year, up from their prior forecast of ($0.21). Zacks Investment Research also issued estimates for DURECT Corporation’s FY2018 earnings at ($0.14) EPS.

A number of other research firms have also weighed in on DRRX. HC Wainwright lowered shares of DURECT Corporation from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Friday, October 20th. Laidlaw cut their price objective on shares of DURECT Corporation from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, October 20th. Stifel Nicolaus lowered shares of DURECT Corporation from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. Finally, ValuEngine raised shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th.

COPYRIGHT VIOLATION WARNING: “DURECT Corporation (DRRX) to Post FY2017 Earnings of ($0.13) Per Share, Zacks Investment Research Forecasts” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://theolympiareport.com/2017/11/06/durect-corporation-drrx-to-post-fy2017-earnings-of-0-13-per-share-zacks-investment-research-forecasts.html.

DURECT Corporation (NASDAQ DRRX) opened at $0.95 on Monday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.57 and a current ratio of 1.67. DURECT Corporation has a 52-week low of $0.74 and a 52-week high of $2.17.

DURECT Corporation (NASDAQ:DRRX) last posted its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.09. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $5.09 million. DURECT Corporation had a negative net margin of 62.57% and a negative return on equity of 419.65%.

Hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC increased its position in DURECT Corporation by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after purchasing an additional 15,394 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in DURECT Corporation during the second quarter worth approximately $151,000. The Manufacturers Life Insurance Company increased its position in DURECT Corporation by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock worth $189,000 after purchasing an additional 13,072 shares during the last quarter. SG Americas Securities LLC acquired a new position in DURECT Corporation during the first quarter worth approximately $147,000. Finally, Rhumbline Advisers increased its position in DURECT Corporation by 12.0% during the second quarter. Rhumbline Advisers now owns 175,604 shares of the specialty pharmaceutical company’s stock worth $274,000 after purchasing an additional 18,871 shares during the last quarter. 46.51% of the stock is owned by hedge funds and other institutional investors.

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Earnings History and Estimates for DURECT Corporation (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.